Literature DB >> 12631706

Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point.

Christoph Schorl1, John M Sedivy.   

Abstract

c-myc is an important protooncogene whose misregulation is believed to causally affect the development of numerous human cancers. c-myc null rat fibroblasts are viable but display a severe (two- to threefold) retardation of proliferation. The rates of RNA and protein synthesis are reduced by approximately the same factor, whereas cell size remains unaffected. We have performed a detailed kinetic cell cycle analysis of c-myc(-/-) cells by using several labeling and synchronization methods. The majority of cells (>90%) in asynchronous, exponential phase c-myc(-/-) cultures cycle continuously with uniformly elongated cell cycles. Cell cycle elongation is due to a major lengthening of G(1) phase (four- to fivefold) and a more limited lengthening of G(2) phase (twofold), whereas S phase duration is largely unaffected. Progression from mitosis to the G1 restriction point and the subsequent progression from the restriction point into S phase are both drastically delayed. These results are best explained by a model in which c-Myc directly affects cell growth (accumulation of mass) and cell proliferation (the cell cycle machinery) by independent pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631706      PMCID: PMC151562          DOI: 10.1091/mbc.e02-10-0649

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  70 in total

Review 1.  G1 events and regulation of cell proliferation.

Authors:  A B Pardee
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

Review 2.  Proteins of the Myc network: essential regulators of cell growth and differentiation.

Authors:  M Henriksson; B Lüscher
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

3.  Immediate effects of serum depletion on dissociation between growth in size and cell division in proliferating 3T3 cells.

Authors:  O Larsson; E Dafgård; W Engström; A Zetterberg
Journal:  J Cell Physiol       Date:  1986-05       Impact factor: 6.384

Review 4.  Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death.

Authors:  B Amati; H Land
Journal:  Curr Opin Genet Dev       Date:  1994-02       Impact factor: 5.578

Review 5.  What is the restriction point?

Authors:  A Zetterberg; O Larsson; K G Wiman
Journal:  Curr Opin Cell Biol       Date:  1995-12       Impact factor: 8.382

6.  Microinjected c-myc as a competence factor.

Authors:  L Kaczmarek; J K Hyland; R Watt; M Rosenberg; R Baserga
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

7.  Identification of c-myc responsive genes using rat cDNA microarray.

Authors:  Q M Guo; R L Malek; S Kim; C Chiao; M He; M Ruffy; K Sanka; N H Lee; C V Dang; E T Liu
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

8.  Effects of c-myc expression on proliferation, quiescence, and the G0 to G1 transition in nontransformed cells.

Authors:  M Shichiri; K D Hanson; J M Sedivy
Journal:  Cell Growth Differ       Date:  1993-02

9.  p53-independent increase in p21WAF1 and reciprocal down-regulation of cyclin A and proliferating cell nuclear antigen in bromodeoxyuridine-mediated growth arrest of human melanoma cells.

Authors:  M Strasberg Rieber; D R Welch; M E Miele; M Rieber
Journal:  Cell Growth Differ       Date:  1996-02

10.  A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice.

Authors:  A C Davis; M Wims; G D Spotts; S R Hann; A Bradley
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

View more
  26 in total

1.  Role for BRG1 in cell cycle control and tumor suppression.

Authors:  Kristin B Hendricks; Frances Shanahan; Emma Lees
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover.

Authors:  Nikita Popov; Christina Schülein; Laura A Jaenicke; Martin Eilers
Journal:  Nat Cell Biol       Date:  2010-09-19       Impact factor: 28.824

3.  Deregulation of common genes by c-Myc and its direct target, MT-MC1.

Authors:  Kenneth R Rogulski; Debra E Cohen; David L Corcoran; Panayiotis V Benos; Edward V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 4.  Analysis of cell cycle phases and progression in cultured mammalian cells.

Authors:  Christoph Schorl; John M Sedivy
Journal:  Methods       Date:  2007-02       Impact factor: 3.608

5.  Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry.

Authors:  Amit Kumar; Miriam Marqués; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2006-10-02       Impact factor: 4.272

6.  Kinetic profiling of the c-Myc transcriptome and bioinformatic analysis of repressed gene promoters.

Authors:  Chui-Sun Yap; Abigail L Peterson; Gastone Castellani; John M Sedivy; Nicola Neretti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

7.  A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression.

Authors:  Gregory S Yochum; Ryan Cleland; Richard H Goodman
Journal:  Mol Cell Biol       Date:  2008-10-13       Impact factor: 4.272

8.  c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry.

Authors:  F Morrish; N Isern; M Sadilek; M Jeffrey; D M Hockenbery
Journal:  Oncogene       Date:  2009-05-18       Impact factor: 9.867

9.  The cell cycle time of CD8+ T cells responding in vivo is controlled by the type of antigenic stimulus.

Authors:  Heesik Yoon; Taeg S Kim; Thomas J Braciale
Journal:  PLoS One       Date:  2010-11-08       Impact factor: 3.240

10.  cMyc increases cell number through uncoupling of cell division from cell size in CHO cells.

Authors:  Darrin Kuystermans; Mohamed Al-Rubeai
Journal:  BMC Biotechnol       Date:  2009-09-07       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.